



## Press Release

### Improved monitoring of blood glucose for diabetes patients

#### Eyesense and Capsulation sign development contract

**Berlin, June 30<sup>th</sup> 2006** - The swiss company Eyesense AG and the Berlin based Capsulation Nanoscience AG have recently signed a development contract aiming at the development of innovative and more user friendly products for diabetes patients to monitor blood sugar levels.

These products for a pain free and more reliable measurement of blood sugar levels are being developed under the direction of Eyesense AG. "The new product eases the procedure for frequent blood glucose level measures and helps diabetes patients to control and maintain healthy blood glucose levels.", said Dr. Peter Herbrechtsmeier, CEO of Eyesense. Thereby common sequela of diabetes, for example cardiovascular disease or loss of sight, can be reduced.

Both companies count on their long experience in joint developmental work. Capsulation makes a major contribution to the product by taking advantage of its tunable nano-capsules. The biocompatible capsules ensure the measurement of the blood glucose near the human eye. The frequent measurement of the blood sugar concentration is performed by a special portable measuring instrument developed by Eyesense.

#### For further information please contact:

##### **Eyesense AG**

Dr. Peter Herbrechtsmeier, CEO  
Stockstaedter Strasse 17  
D-63762 Großostheim  
Telefon: +49 (0) 6022 942120  
[peter.herbrechtsmeier@eyesense.com](mailto:peter.herbrechtsmeier@eyesense.com)  
[www.eyesense.com](http://www.eyesense.com)

##### **Capsulation Nanoscience AG**

Herr Dipl.-Kfm. Alexander Herrmann  
Telefon: +49 (0)30-63 92 36 00  
Fax: +49 (0)30-63 92 36 01  
[alexander.herrmann@capsulation.com](mailto:alexander.herrmann@capsulation.com)

**About Eyesense AG:**

EyeSense AG is a venture-backed diagnostic device company based in Basel and operations close to Frankfurt a. Main, Germany. Eyesense was founded in 2006 as a spin-out from Ciba Vision AG (a Novartis company) and develops ophthalmic diagnostic systems focusing on glucose testing for diabetic patients. In addition to glucose, the testing platform being developed by Eyesense has the potential to measure a broad variety of medical-relevant analytes in patients.

**About Capsulation NanoScience AG**

Capsulation NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on nano-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer. In order to meet customers needs for complete product solutions Capsulation has recently designated a Japanese licensee as the preferred developer, manufacturer and distributor for automated LBL-units. Only six month after the signing of the licence agreement, EBARA has started operation of the first prototype plant (LBL-Unit®) for the manufacture of Capsulation's LBL capsules. In 2005, renowned growth consultants Frost & Sullivan have awarded the year's "Product Differentiation Innovation Award" in the global nanobiotechnology market to Capsulation NanoScience AG, Berlin. The company has received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications.

Press Release and Press Box online:

<http://www.pressebox.de/pressefach/capsulation-nanoscience-ag>